In recent decades, a series of HCAR2 agonists have been successfully discovered and four of them, including niacin, acipimox, acifran, and MMF, have been approved for clinical treatment of cardiovascular and neurological disorders, such as dyslipidemia, atherosclerosis, and relapsing multiple sclerosis13. The gene discussed is HCAR2; the disease is metabolic syndrome.